MedTrace Logo

ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction

NCT02709798 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-08-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether perioperative use of Shenfu Injection could reduce myocardial injury (enzymatic infarct size and infarct volume according to cardiac magnetic resonance imaging) in patients with STEMI after primary PCI

Conditions

Interventions

DRUG

Shenfu Injection

DRUG

5% Glucose Injection

Sponsors & Collaborators

  • China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Beijing Anzhen Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02709798 on ClinicalTrials.gov